SELLAS Life Sciences enrolls first patient in phase 2 AML trial
Go back to SELLAS Life Sciences enrolls first patient in phase 2 AML trial| RiverSource LaSalle Internatio (NASDAQ: SLS) | Delayed: 13.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.50 | 52 Week High | $10.16 | |||
| Open | $13.50 | 52 Week Low | $6.52 | |||
| Day High | $13.50 | P/E | N/A | |||
| Day Low | $13.50 | EPS | $0.00 | |||
| Volume | 161,178 | |||||
